How to think outside the box — according to research

create change

What happens to creativity when those who use a particular thinking style tried a different approach? Getty Images

Creativity is an essential ingredient in problem-solving, and the importance of "thinking outside the box" has been stressed in nearly every context imaginable, business or otherwise. But that mantra assumes — wrongly — that we all start off thinking inside the same sort of cognitive box.

Instead, each person has a distinctive cognitive style: some of us, for example, are more intuitive, and others approach the world more rationally. What happens to creativity when those who use a particular thinking style tried a different approach?

Rice Business Professor Erik Dane decided to investigate. Along with colleagues Markus Baer of Washington University in St. Louis, Michael Pratt of Boston College, and Greg Oldham of Tulane University Dane studied typical thinking styles, rational versus and intuitive, and how resisting the most familiar one can affect creativity.

Rational thinkers, the professors noted, learn information deliberately and engage in thoughtful analysis. They depend on a linear, or sequential, way of processing information. Intuitive thinking, meanwhile, is an unconscious way of processing information. It's essentially the opposite of rational thinking: quick and holistic, rather than deliberate and comprehensive.

When a rational thinker faces a problem, her mind goes through multiple stages, tapping relevant mental data bases and coming up with alternative solutions. Her mind evaluates and refines these scenarios to choose the best possible solution to the problem.

An intuitive thinker, on the other hand, goes with his gut. Many researchers believe this type of thinking sparks creativity because it integrates so many different pieces of experience.

To explore what happens when one type of thinker follows a different approach, Dane and his fellow researchers colleagues gave test subjects a scenario. How could they get more students to come into a gift shop? Participants first had to come up with ideas using either an intuitive or a rational problem-solving approach. Then they filled out a short questionnaire. Afterward, the professors evaluated the ideas as creative or not creative, based on originality and usefulness.

When a participant wasn't used to rational thinking and had to problem-solve using a more rational approach, he or she came up with more creative ideas, the researchers found. This, the researchers said, suggests it's worth encouraging intuitive thinkers to change up their problem-solving style to come up with new ideas.

Curiously, it's relatively easy to influence a person's cognitive approach to a problem, the researchers found. At the same time, the research didn't suggest that either approach — rational or intuitive thinking — was inherently better than the other. In fact, they wrote, future research on the topic ought to analyze what happens when subjects are encourage to take a hybrid rational-intuitive approach.

In the meantime, whether you're trying to lure customers to your new coffee shop, or figuring out the best ending to your crime novel, try attacking the problem with the thinking style that's least familiar to you. To truly think outside the box, the first thing to do is peer over the side to see what style of thinking most often boxes you in.

------

This article originally appeared on Rice Business Wisdom.

Erik Dane is an associate professor of management at the Jones Graduate School of Business at Rice University.

Researchers found that there's still very little conceptual explanation for how individual creative attempts become organizational innovation. Getty Images

Researchers find there's not much data on how creativity becomes change in the workplace

Houston Voices

Innovation and creativity are crucial tools that all businesses need in order to prosper. Research into how these tools work covers a broad area and crosses various disciplines. In the past, much of this research has been divided: One side looked at innovation, which focuses on how ideas are implemented, while the other examined creativity, which focuses on coming up with new ideas. Rice Business Professor Jing Zhou and colleagues addressed this divide by reviewing research going back a little more than a decade, looking for key measures that could be used as guidelines for future research.

Zhou and her colleagues began their work by reviewing the practical and theoretical perspectives of innovation and creativity in the workplace. They then created a framework for future research after identifying prominent theories.

Before getting started, however, they needed clear definitions for both innovation and creativity. Creativity, Zhou proposed, centers on idea generation. It's the first step toward innovation. Innovation, she concluded, stresses the implementation of ideas. This happens at different levels: individual, team, organization, or across multiple levels.

At the team level of innovation, research has progressed significantly, the authors found. They suggest that researchers now focus on other aspects of team-level research, such as team environment, leadership and facilitators of workgroups.

At the organizational level, Zhou and her colleagues found that numerous studies looked at the factors that influence innovation. But, they concluded, there's still very little conceptual explanation for how individual creative attempts become organizational innovation.

The team's review reveals the enormous strides that researchers have made in the field of creativity and innovation in recent years, and clarifies how their studies have been used by different organizations.

Despite advances in the field, however, there are still shortcomings. Many studies, for example, are hampered by problematic research approaches. Some lack theoretical groundwork and few take an inclusive approach to multi-level studies.

Zhou and her colleagues argue that addressing these limitations would be a tremendous leap forward in understanding creativity and innovation in the workplace. Without innovation, companies can't prosper and progress. The same holds true for academic research into these lifelines of business success: It will need to expand and dig deeper or cease to be relevant in practice.

------

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Houston Endowment Professor of Management and Director for Asian Management Research and Education at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings